Exelixis (NASDAQ:EXEL) has been on a tear over the last year, nearly quadrupling.
While much of the growth in Exelixis’ stock price has to do with the better-than-expected launch of Cabometyx in kidney cancer, the biotech still has room to run.
Exelixis (NASDAQ:EXEL) has been on a tear over the last year, nearly quadrupling.
While much of the growth in Exelixis’ stock price has to do with the better-than-expected launch of Cabometyx in kidney cancer, the biotech still has room to run.
